Clinical Trial Update: MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/Phase 2 study exploring a MAPK pathway inhibitor in combination with anti-PD1 therapy for BRAF-altered pediatric …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade Glioma
• Low-grade Glioma

Snippet

Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago | Conditions: Low Grade Glioma, High Grade Glioma | Phase 1, Phase 2 | Status: RECRUITING